^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGF19 positive

    i
    Other names: FGF19, Fibroblast growth factor 19
    Entrez ID:
    9965
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Investigation of the Proliferative Potential of FGF21 or FGF19 in Liver-Specific FGFR4-Deficient Mice. (PubMed, Toxicol Pathol)
    The results showed a statistically significant increase in FGF21- and FGF19-treated Fgfr4 fl/fl mice. Interestingly, in Fgfr4 KO mice, this effect was absent following both treatments of FGF19 and FGF21, indicating that not only the FGFR4 receptor is pivotal for the mediation of hepatocellular proliferation by FGF19 leading finally to liver tumors but it seems also that FGFR4/FGF21 signaling has an impact on the hepatocellular proliferative activity, which does not promote the formation of hepatocellular liver tumors based on the current knowledge.
    Preclinical • Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • FGF21 (Fibroblast Growth Factor 21)
    |
    FGF19 positive
    over1year
    Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Trial primary completion date: May 2023 --> Sep 2023
    Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    FGF19 (Fibroblast growth factor 19)
    |
    FGF19 positive
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    over1year
    A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. (PubMed, Invest New Drugs)
    Preliminary data showed that BLU-554 in combination with CS1001 is safe and effective for treatment of patients with locally advanced or metastatic HCC.
    P1/2 data • Clinical Trial,Phase I • Journal • Combination therapy • Metastases
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4)
    |
    FGF19 positive
    |
    Cejemly (sugemalimab) • fisogatinib (BLU-554)
    2years
    FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma. (PubMed, Proc Natl Acad Sci U S A)
    Genome-wide CRISPR loss-of-function screening revealed that FGFR3 restricted the activity of FGFR4-selective inhibitors in inducing cell death; the pan-FGFR inhibitor erdafitinib displayed superior potency than FGFR4-selective inhibitors in suppressing the growth and survival of FGF19-positive HCC cells. Among FGF19-positive HCC cases from The Cancer Genome Atlas (TCGA), FGFR3 is prevalently coexpressed with FGFR4 and KLB, suggesting that FGFR redundancy may be a common mechanism underlying the de novo resistance to FGFR4 inhibitors. Our study provides a rationale for clinical testing of pan-FGFR inhibitors as a treatment strategy for FGF19-positive HCC.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • KLB (Klotho Beta)
    |
    FGF19 positive
    |
    Balversa (erdafitinib)
    over3years
    Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • IO biomarker
    |
    FGF19 (Fibroblast growth factor 19)
    |
    FGF19 positive
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    over3years
    Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Mayo Clinic
    Clinical • New P2 trial • Combination therapy • IO biomarker
    |
    FGF19 (Fibroblast growth factor 19)
    |
    FGF19 positive
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    almost4years
    FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Recruiting, EverNov Medicines (Zhuhai Hengqin) Co., Ltd
    Clinical • New P1/2 trial • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    FGF19 (Fibroblast growth factor 19)
    |
    FGF19 positive • FGF19 expression
    |
    Keytruda (pembrolizumab) • roblitinib (FGF401)